144 related articles for article (PubMed ID: 12771302)
1. Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
Koiwa F; Hasegawa T; Kojima I; Ideura T
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii53-7. PubMed ID: 12771302
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
[TBL] [Abstract][Full Text] [Related]
3. Renoprotection following treatment of secondary hyperparathyroidism with percutaneous ethanol injection in pre-dialysis patients.
Chen HH; Chen YC; Yeh JC
Nephron; 2002 Sep; 92(1):105-10. PubMed ID: 12187092
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):48-52. PubMed ID: 15828906
[TBL] [Abstract][Full Text] [Related]
5. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
[TBL] [Abstract][Full Text] [Related]
6. Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography.
Tanaka R; Kakuta T; Fujisaki T; Tanaka S; Sakai H; Kurokawa K; Saito A
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii58-61. PubMed ID: 12771303
[TBL] [Abstract][Full Text] [Related]
7. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
Ito H; Ogata H; Yamamoto M; Takahashi K; Shishido K; Takahashi J; Taguchi S; Kinugasa E
Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism.
de Barros Gueiros JE; Chammas MC; Gerhard R; da Silva Dias Boilesen CF; de Oliveira IR; Moysés RM; Jorgetti V
Nephrol Dial Transplant; 2004 Mar; 19(3):657-63. PubMed ID: 14767023
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism.
Koiwa F; Kakuta T; Tanaka R; Yumita S
Nephrol Dial Transplant; 2007 Feb; 22(2):522-8. PubMed ID: 17127701
[TBL] [Abstract][Full Text] [Related]
10. Treatment of refractory secondary hyperparathyroidism with ethanol injection: the importance of glandular volume.
Douthat WG; Orozco SE; de Arteaga J; Massari PU
Kidney Int Suppl; 2003 Jun; (85):S101-4. PubMed ID: 12753277
[TBL] [Abstract][Full Text] [Related]
11. Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism.
Costa AF; dos Reis LM; Ribeiro MC; Moysés RM; Jorgetti V
Nephrol Dial Transplant; 2003 Apr; 18(4):743-9. PubMed ID: 12637644
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. [Calcitriol dose optimization in the treatment of secondary hyperparathyroidism during dialysis. Results at 6 months].
Rodríguez García M; Fernández Martín JL; Ruiz de Castañeda J; Hervás Sánchez J; Cannata Andía JB;
Nefrologia; 2002; 22(4):370-6. PubMed ID: 12369129
[TBL] [Abstract][Full Text] [Related]
14. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
Caravaca F; Cubero JJ; Jimenez F; López JM; Aparicio A; Cid MC; Pizarro JL; Liso J; Santos I
Nephrol Dial Transplant; 1995; 10(5):665-70. PubMed ID: 7566580
[TBL] [Abstract][Full Text] [Related]
15. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
[TBL] [Abstract][Full Text] [Related]
16. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
Takahashi F; Furuichi T; Yorozu K; Kawata S; Kitamura H; Kubodera N; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():46-52. PubMed ID: 12386269
[TBL] [Abstract][Full Text] [Related]
17. [A case of secondary hyperparathyroidism with an ectopic intrathyroid gland successfully diagnosed and controlled by percutaneous ethanol injection therapy (PEIT)].
Tanaka M; Itoh K; Matsushita K; Ogawa A; Hirayama H; Tsunoda N; Yoshizumi K; Naruse M; Nonoguchi H; Tomita K
Nihon Jinzo Gakkai Shi; 2002 May; 44(4):409-13. PubMed ID: 12073627
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism.
Nakamura M; Fuchinoue S; Teraoka S
Am J Kidney Dis; 2003 Oct; 42(4):739-45. PubMed ID: 14520624
[TBL] [Abstract][Full Text] [Related]
19. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
20. Role of the parathyroid gland vascularization index in predicting percutaneous ethanol injection efficacy in refractory uremic hyperparathyroidism.
Chen HH; Lu KC; Lin CJ; Wu CJ
Nephron Clin Pract; 2011; 117(2):c120-6. PubMed ID: 20693813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
